A Hidden Epidemic: Addressing Visceral Fat and Insulin Resistance in Non-Obese T2DM with Pioglitazone-Based Therapies Dr. K M Suryanarayana VSM5 Nov 2025 11:15 AM ISTMetabolically unhealthy non-obese individuals (MUNO) comprise around 20% of the normal-weight population and have a 3.14-fold higher risk of...
Prediabetes and Cancer Risk: The Overlooked Connection Dr. Khushboo Agarwal3 Nov 2025 11:10 AM ISTPrediabetes burden is rising globally and in India. The latest IDF 2025 Atlas estimated that in 2024, 634.8 million adults (12%) worldwide had IGT,...
Dapagliflozin and Sitagliptin FDC: Exploring Early Initiation Benefits In Young Newly Diagnosed T2D in India Dr. Rajiv Kovil1 Nov 2025 10:34 AM ISTType 2 diabetes (T2D) is a growing epidemic in India. India has 101 million people with diabetes and 136 million with prediabetes, with disease onset...
Advancements in Antifungal Treatment: Insights from In vitro Trials with Selenium Sulfide Dr. Kamal Kant Kohli30 Oct 2025 11:15 AM ISTFungal infections represent a significant challenge in human medicine. With increasing resistance to conventional antifungal therapies and the...
India's Unique CV Risk Profile: How to Decode the Role of Aspirin? Dr. Ajay U. Mahajan7 Oct 2025 11:47 AM ISTCardiovascular disease remains one of the dominant non-communicable causes of death in India, contributing substantially to premature morbidity and...
Identifying Aspirin Candidates for Primary Prevention: Focus on Men Aged 40- 50 with Metabolic Syndrome and Cardiometabolic Risk Lalhmangaihkimi29 Sept 2025 12:15 PM ISTUnique CV Risk in India- Epidemiological BackdropCardiovascular diseases (CVDs) remain the leading cause of death in India, with a WHO-reported...
Undenatured Collagen in Osteoarthritis Management: Practitioner's Review in 2025 Naresh Pincha22 Sept 2025 11:18 AM ISTOsteoarthritis is the most prevalent musculoskeletal disorder globally and the leading cause of chronic pain and disability. In India, over 62 million...
Exploring Buccal Prochlorperazine: A Targeted Review of Its Pharmacological Profile Dr. Kamal Kant Kohli9 Sept 2025 12:15 PM ISTThe Clinical Value of Buccal ProchlorperazineProchlorperazine remains a clinically valuable agent for managing nausea, dizziness, vertigo, and...
Overcoming Antifungal Resistance: The Case for Selenium Sulfide Dr. Kamal Kant Kohli5 Sept 2025 12:30 PM ISTThe rising incidence of fungal infections and increasing resistance to antifungal treatments present significant global health challenges, accompanied...
The Forgotten Insulin Sensitizer: Revisiting Pioglitazone for Metabolically Unhealthy Non-Obese (MUNO) Indians with T2DM Dr. Arvind Gupta25 Aug 2025 10:56 AM ISTMUNO Indian Phenotype: A Silent High-Risk Candidate The Metabolically Unhealthy Non-Obese (MUNO) phenotype is a silent but high-risk profile,...
Young, Diabetic, and at High CV Risk: Is It Time for Early Aspirin? Dr. Amit V. Joshi18 Aug 2025 11:47 AM ISTYoung, Diabetic, and at High CV Risk: A Case for Early CV Prevention with Aspirin in the High-Risk Young
Twelve Co-morbidities' Association and Risks Associated with Prediabetes-Evidence Every Clinician Must Know Dr. Ramdas Bharat Barure14 Aug 2025 10:50 AM ISTAugust 14 has been marked as World Prediabetes Day, set 90 days before World Diabetes Day (November 14), the typical timeframe needed to achieve a...
